Holen Sie sich die Stockscreener-App
3.305
6.27%
0.195
Schlusskurs vom Vortag:
$3.11
Offen:
$3.14
24-Stunden-Volumen:
608.64K
Relative Volume:
0.78
Marktkapitalisierung:
$137.63M
Einnahmen:
$123.87M
Nettoeinkommen (Verlust:
$62.49M
KGV:
1.9796
EPS:
1.6695
Netto-Cashflow:
$-87.53M
1W Leistung:
+6.96%
1M Leistung:
-15.26%
6M Leistung:
-27.36%
1J Leistung:
-13.48%
1-Tages-Spanne:
$3.14
$3.42
1-Wochen-Bereich:
$3.05
$3.42
52-Wochen-Spanne:
$2.71
$7.34
Agenus Inc Stock (AGEN) Company Profile
Firmenname
Agenus Inc
Sektor
Branche
Telefon
781-674-4410
Adresse
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.305 | 129.51M | 123.87M | 62.49M | -87.53M | 1.6695 |
VRTX
Vertex Pharmaceuticals Inc
|
436.69 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.92 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.45 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.62 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.25 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-02-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-28 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-04-22 | Eingeleitet | B. Riley FBR | Buy |
| 2016-10-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Bestätigt | Maxim Group | Buy |
| 2016-03-11 | Hochstufung | Maxim Group | Hold → Buy |
| 2015-12-16 | Eingeleitet | Jefferies | Buy |
| 2015-10-27 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-07-27 | Bestätigt | MLV & Co | Buy |
| 2015-06-11 | Eingeleitet | Oppenheimer | Outperform |
| 2015-01-12 | Bestätigt | Maxim Group | Buy |
| 2015-01-09 | Bestätigt | MLV & Co | Buy |
| 2015-01-09 | Bestätigt | Maxim Group | Buy |
| 2014-12-19 | Bestätigt | Maxim Group | Buy |
| 2014-05-08 | Bestätigt | Maxim Group | Buy |
| 2014-03-14 | Bestätigt | MLV & Co | Buy |
| 2013-10-08 | Bestätigt | Maxim Group | Buy |
| 2012-01-05 | Eingeleitet | William Blair | Outperform |
| 2011-12-01 | Eingeleitet | Global Hunter Securities | Buy |
Alle ansehen
Agenus Inc Aktie (AGEN) Neueste Nachrichten
How Agenus' Pipeline Progress Unlock Its Next Growth Phase - TradingView
Agenus: Weighing The Clinical Progress Against The Company's Cash (NASDAQ:AGEN) - Seeking Alpha
BOT+BAL Demonstrates Durable Immune Benefit in Advanced Melanoma – Agenus - Oncodaily
Agenus reports melanoma trial data for checkpoint therapy By Investing.com - Investing.com South Africa
AGEN News | AGENUS INC (NASDAQ:AGEN) - ChartMill
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 - BioSpace
AI model identifies colorectal cancer patients likely to respond - Investing.com UK
Agenus reports melanoma trial data for checkpoint therapy - Investing.com UK
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC - 01net
New melanoma drug combo sees 42% of patients alive at 2 years - Stock Titan
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell? - TradingView
AGEN Technical Analysis | Trend, Signals & Chart Patterns | AGENUS INC (NASDAQ:AGEN) - ChartMill
Agenus (AGEN) chief takes 4,540 common shares as salary - Stock Titan
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer - BioSpace
Agenus (AGEN) price target decreased by 32.61% to 15.81 - MSN
Are options traders betting on a big move in Agenus stock? - MSN
Agenus Inc.Common Stock (NQ: AGEN - FinancialContent
Agenus (AGEN) Reports Phase 1b Results for Innovative Cancer Tre - GuruFocus
Agenus reports phase 1b liver cancer trial results - Investing.com UK
Agenus announces publication of Phase 1b BOT+BAL data - TipRanks
Agenus reports phase 1b liver cancer trial results By Investing.com - Investing.com Nigeria
Agenus Announces Resignation of Principal Accounting Officer - TipRanks
Agenus Announces Publication of Phase 1b Botensilimab and Balstil - The National Law Review
Early drug combo yields responses in liver cancer after immunotherapy - Stock Titan
Agenus (AGEN) Principal Accounting Officer Austin Charette plans May 2026 exit - Stock Titan
Advancing Strategies to Activate and Sustain Immune Response in Harder-to-Treat CancersAgenus - Oncodaily
Agenus (AGEN) Q1 Earnings and Revenues Miss Estimates - Yahoo Finance
Agenus Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Is Agenus (AGEN) Undervalued After Q1 2026? Revenue $33.7M (miss - GuruFocus
Agenus (AGEN) Releases Q1 2026 Earnings: Revenue Growth but EPS Miss - Quiver Quantitative
MSN Money - MSN
Agenus: Q1 Earnings Snapshot - kens5.com
AGENUS INC 1Q 2026: Revenue $33.7M, EPS $1.02— 10-Q Summary - TradingView
[10-Q] AGENUS INC Quarterly Earnings Report - Stock Titan
Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Agenus (AGEN) Marks Significant Progress in Q1 2026 - GuruFocus
Agenus (AGEN) Cleared of SEC Investigation and Court Dismisses S - GuruFocus
Agenus reports Q1 results, Phase 3 trial enrollment begins By Investing.com - Investing.com South Africa
Agenus (AGEN) Reports Significant Increase in Cash Reserves - GuruFocus
Agenus reports Q1 results, Phase 3 trial enrollment begins - Investing.com
Immuno-oncology developer Agenus' Q1 revenue rises, posts profit - TradingView
Zydus collaboration lifts Agenus (Nasdaq: AGEN) to Q1 2026 profit - Stock Titan
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development - marketscreener.com
Number of shareholders of Agenus Inc. – NASDAQ:AGEN - TradingView
Finanzdaten der Agenus Inc-Aktie (AGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):